The group's principal activity is the research and development of novel therapeutic and diagnostic products to treat chronic debilitating diseases such as cancer and central nervous system disorders. Still in its development stages, the group has eleven technologies in its product portfolio, which were invented or discovered by researchers working at the harvard university and its affiliated hospitals and has been exclusively licensed to the group. They include the altropane(tm) imaging agent, a small molecule being developed as a diagnostic for Parkinson's disease and attention deficit hyperactivity disorder. The group owns the exclusive license for the use of troponin to treat a variety of angiogenic diseases. The group has acquired the rights for inosine and af-1, which are nerve growth factors, specifically promoting axon outgrowth in cns cells.
